Published in Prostate on February 01, 2011
Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNA. Inorg Chem (2011) 0.98
Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents. Organometallics (2012) 0.87
CGK733 does not inhibit ATM or ATR kinase activity in H460 human lung cancer cells. DNA Repair (Amst) (2011) 0.79
Novel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents. J Inorg Biochem (2015) 0.79
H2AX phosphorylation and DNA damage kinase activity are dispensable for herpes simplex virus replication. Virol J (2016) 0.77
Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology (2008) 2.75
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2012) 2.60
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Side-effects of treatments for locally advanced prostate cancer. BJU Int (2006) 2.03
Benign prostatic hyperplasia: counting the cost of its management. BJU Int (2010) 1.64
RPA phosphorylation in mitosis alters DNA binding and protein-protein interactions. Biochemistry (2003) 1.63
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Optimising repeat prostate biopsy decisions and procedures. BJU Int (2011) 1.62
Heat shock proteins: their role in urological tumors. J Urol (2003) 1.56
Indicators for research performance evaluation: an overview. BJU Int (2012) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int (2004) 1.53
Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol (2006) 1.44
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Radical prostatectomy vs watchful waiting. BJU Int (2005) 1.41
Can lifestyle modification lower the risk of prostate cancer? BJU Int (2010) 1.40
Fibrogenesis in Crohn's disease. Am J Gastroenterol (2006) 1.39
Current prospects for the chemoprevention of prostate cancer. BJU Int (2010) 1.39
Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence? BJU Int (2008) 1.39
Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer (2003) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol (2005) 1.33
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genet (2009) 1.21
Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2010) 1.20
Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chem Soc Rev (2008) 1.17
Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int (2010) 1.16
Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) (2005) 1.16
Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate (2002) 1.15
Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin. DNA Repair (Amst) (2008) 1.12
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate (2007) 1.10
Electronic learning can facilitate student performance in undergraduate surgical education: a prospective observational study. BMC Med Educ (2005) 1.09
Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer (2009) 1.08
Biomarker research in prostate cancer--towards utility, not futility. Nat Rev Urol (2011) 1.07
Epidemiology of testicular cancer. BJU Int (2009) 1.06
Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine (Phila Pa 1976) (2002) 1.04
The apoptosome pathway to caspase activation in primary human neutrophils exhibits dramatically reduced requirements for cytochrome C. J Exp Med (2003) 1.04
BMI and the risk of renal cell carcinoma. Curr Opin Urol (2011) 1.03
Ionizing radiation-dependent and independent phosphorylation of the 32-kDa subunit of replication protein A during mitosis. Nucleic Acids Res (2009) 1.00
Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood (2003) 1.00
Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or γ-irradiation. Cell Cycle (2011) 0.99
Targeting death receptors in bladder, prostate and renal cancer. J Urol (2006) 0.99
Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle (2009) 0.99
In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anticancer Drugs (2005) 0.99
Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anticancer Drugs (2006) 0.98
Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney. Kidney Blood Press Res (2007) 0.98
2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res (2009) 0.98
Exploring mechanisms involved in renal tubular sensing of mechanical stretch following ureteric obstruction. Am J Physiol Renal Physiol (2008) 0.98
Androgen-mediated resistance to apoptosis. Prostate (2002) 0.97
Delayed graft function: a dilemma in renal transplantation. BJU Int (2005) 0.97
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther (2009) 0.97
Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins. BJU Int (2004) 0.96
Antiproliferative activity of Titanocene Y against tumor colony-forming units. Anticancer Drugs (2007) 0.96
The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int (2008) 0.95
Mechanical deformation induced apoptosis in human proximal renal tubular epithelial cells is caspase dependent. J Urol (2004) 0.95
Biomarkers in renal cell carcinoma. Curr Opin Urol (2009) 0.95
Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour. Eur J Pharmacol (2006) 0.94
Mechanical stretch regulates cell survival in human bladder smooth muscle cells in vitro. Am J Physiol Renal Physiol (2002) 0.93
Titanocene difluorides with improved cytotoxic activity. Inorg Chem (2010) 0.93
DNA polymerase eta, a key protein in translesion synthesis in human cells. Subcell Biochem (2010) 0.93
An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate (2004) 0.93
Epstein criteria for insignificant prostate cancer. BJU Int (2011) 0.93
Heteroaryl substituted titanocenes as potential anti-cancer drugs. J Inorg Biochem (2006) 0.93
Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res (2011) 0.91
Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay. Toxicol In Vitro (2007) 0.91
Chemotherapy for older patients with prostate cancer. BJU Int (2006) 0.90
Novel achiral titanocene anti-cancer drugs synthesised from bis-N,N-dimethylamino fulvene and lithiated heterocyclic compounds. Biometals (2007) 0.90
Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int (2011) 0.90